Vimarsana
Biggest News Aggregation in the World

Paper Session News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Paper Session. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Paper Session Today - Breaking & Trending Today

GATE Chemical Engineering Question Paper with Solution, Download Previous Year Question Paper PDF - Vimarsana News

GATE Chemical Engineering Question Paper with Solution, Download Previous Year Question Paper PDF

GATE Chemical Engineering (CH) Previous Year Paper: Download GATE Chemical Engineering previous year question papers pdf for the past 10 years. All the candidates of GATE 2024 are advised to solve the GATE Chemical Engineering previous year's question paper to understand the structure and the difficulty level of the exam.

Innate Pharma Announces Abstracts Selected for ESMO Congress 2023 - Vimarsana News

Innate Pharma Announces Abstracts Selected for ESMO Congress 2023

MARSEILLE, France, October 16, 2023--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that the following presentations will be presented at the European Society for Medical Oncology (ESMO) Congress 2023, taking place October 20-24 in Madrid, Spain.

Source: yahoo.com
Enterome to Present Data on EO2401 in Adrenal Tumors at the European Society for Medical Oncology (ESMO) 2023 Congress - Vimarsana News

Enterome to Present Data on EO2401 in Adrenal Tumors at the European Society for Medical Oncology (ESMO) 2023 Congress

Oral Presentation at ESMO will feature updated results from Phase 1/2 SPENCER studyPARIS, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its unique Mimicry platform, today announced that updated data from its Phase 1/2 SPENCER study on EO2401, in combination with nivolumab in patients with adrenal tumors, will be presented in an oral session at the European

Source: yahoo.com
High-Dose Aflibercept Sustains Outcomes Over 96 Weeks - Vimarsana News

High-Dose Aflibercept Sustains Outcomes Over 96 Weeks

The recently approved 8-mg dose of aflibercept has shown sustained improvement in vision and anatomical markers out to 96 weeks, according to updated clinical trial results.

Ocuphire Pharma to Present at Euretina and Retina Society Conferences in October - Vimarsana News

Ocuphire Pharma to Present at Euretina and Retina Society Conferences in October

Presentations Will Feature Data From ZETA-1 Phase 2 Trial of APX3330 in Diabetic RetinopathyFARMINGTON HILLS, Mich., Oct. 06, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced presentations featuring results from the ZETA-1 Phase 2 Trial of APX3330 at the 23rd Euretina Congress to take plac

Source: yahoo.com